Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics for obesity, metabolic diseases, and liver diseases. Its lead product candidate, pemvidutide, is a novel GLP-1/glucagon dual receptor agonist designed to address obesity and metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). Pemvidutide activates GLP-1 to suppress appetite and glucagon to increase energy expenditure and promote hepatic fat metabolism, mimicking effects of diet and exercise. The company is advancing pemvidutide in clinical trials for these indications, leveraging its differentiated profile for potential broader applications. Additionally, Altimmune develops HepTcell, an immunotherapeutic aimed at achieving a functional cure for chronic hepatitis B through Phase II trials conducted internationally. Operating wholly owned subsidiaries supports its global development efforts in peptide therapeutics targeting unmet needs in metabolic and liver health sectors. Founded in 1997 and headquartered in Gaithersburg, Maryland, Altimmune focuses on next-generation treatments in these critical therapeutic areas.